分子靶向药物联合核转录因子kβ抑制剂对胃癌细胞系SNU-1的抑制作用

发布时间：2018-06-24 00:50

本文选题：靶向药物 + 索拉菲尼　；参考：《中国临床药理学杂志》2015年12期

【摘要】：目的探讨索拉菲尼、拉帕替尼联合吡咯烷二硫代氨基甲酸盐(PDTC)对胃癌细胞系SNU-1的增殖、凋亡及细胞周期的影响。方法实验分3大组,分别为空白组、实验组和对照组:空白组(A组),加细胞,再加相应等量的培养基,不加干预药物;实验组再分4组(B、C、D、E组),3.0μmol·L-1索拉菲尼加3.0μmol·L-1拉帕替尼(B组),3.0μmol·L-1索拉菲尼加50.0μmol·L-1PDTC(C组),3.0μmol·L-1拉帕替尼再加50.0μmo·L-1PDTC(D组),3.0μmol·L-1的索拉菲尼加3.0μmol·L-1的拉帕替尼加50μmol·L-1的PDTC(E组);对照组再分3组,分别用低、中、高3种不同浓度的索拉菲尼、拉帕替尼(1.5,6.0,12.0μmol·L-1)和PDTC(25.0,100.0,200.0μmol·L-1)做对照。用MTT法分别检测不用药物组的抑制作用,用流式细胞仪检测各组药物对胃癌细胞周期和细胞凋亡的影响。结果不同药物组对SNU-1都有一定的抑制作用,3种药物联合作用能显著抑制细胞生长(P0.05),显著影响细胞周期(P0.05),显著提高细胞的凋亡率(P0.05)。结论 3种药物联合可以有效地抑制胃癌细胞的增殖。
[Abstract]:Objective to investigate the effects of sorafenil, rapatinib and pyrrolidine dithiocarbamate (PDTC) on the proliferation, apoptosis and cell cycle of gastric cancer cell line SNU-1. Methods the experiment was divided into three groups: blank group, experimental group and control group: blank group (group A), adding cells, adding the corresponding medium, no intervention drug; The experimental group was divided into 4 groups (group B): 3.0 渭 mol L-1 Sorafenil plus 3.0 渭 mol L-1 Rapatinib (Group B), 3.0 渭 mol L-1 Solafini plus 50.0 渭 mol L-1 PDTC (Group C) 3.0 渭 mol L-1 Rapatinib plus 50.0 渭 mol L-1 PDTC (Group D), 3.0 渭 mol L-1 Solafini plus 3.0 渭 mol L-1 Rapatini plus 50 渭 mol PDTC (Group E); Three different concentrations of sorafenil, rapatinib (1.5o6.0U 12.0 渭 mol L-1) and PDTC (25.0100.0200.0 渭 mol L-1) were used as control group. MTT assay was used to detect the inhibitory effect of non-drug group and flow cytometry was used to detect the effect of each group on the cell cycle and apoptosis of gastric cancer cells. Results different drug groups had some inhibitory effects on SNU-1. The combination of three drugs could significantly inhibit cell growth (P0.05), significantly affect cell cycle (P0.05), and significantly increase the rate of cell apoptosis (P0.05). Conclusion the combination of three drugs can effectively inhibit the proliferation of gastric cancer cells.
【作者单位】：河南省人民医院药学部;
【分类号】：R96

【参考文献】